Effects of tiapride on electroencephalograms and cognitive functions in the elderly

Patat, Alain; Alberini, H; Bonhomme, D; Soubrane, Christina; Allain, H.; Gandon, J. M.

doi:10.1097/00004850-199907000-00001

Cited by 11 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The absence of coherence when observing the results obtained on the BS makes difficult any interpretation on the impact of piribedil on the subscores and at different times. The present study performed with a DA agonist appears as very coherent and symmetric when confronting the published results obtained with the same experimental design, with antipsychotics [33,34] which share the pharmacological property to antagonize the brain D 2 dopaminergic receptors [11,39]. Our results are also relevant when compared to the recent study of Nagaraja and Jayashree [8] who demonstrated, after a randomized, double‐blind clinical trial that piribedil (50 mg/day) improves global cognitive function in patients with MCI.…”

Section: Discussionmentioning

confidence: 54%

“…Pairwise comparisons were performed using the Student‐Newman‐Keul's test. The population sample size was based upon previous studies that showed statistically significant effects of psychotropics on cognitive functions and memory tests similar to those used in the present study [32–34]. In the same way, studies with EEG spectral analysis were performed on a similar population sample size [35].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers

Schück

Bentué-Ferrer

Kleinermans

et al. 2002

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Piribedil is a dopamine agonist acting on D2 and D3 central nervous system dopamine receptors. This drug has been administered to 12 young healthy male volunteers (age 22 +/- 2 years) according to a single center randomized, double-blind, two ways cross-over, placebo controlled trial, including a washout period of one week. Placebo and piribedil were administered by a single intravenous infusion over 2 h (3 mg). Psychomotor performance and cognitive functions were assessed through a standardized and computerized psychometric tests battery and a continuous electroencephalogram (EEG) mapping. Piribedil improved simple reaction time (P=0.02), immediate (P=0.045 and 0.004), and delayed free recall (P=0.05), dual coding test (P=0.02) and increased theta and fast beta waves on the EEG (P < 0.05 and 0.001, respectively). No deleterious effect was observed on the tests exploring attention and concentration via the other procedures. It is concluded that a single intravenous perfusion of piribedil 3 mg improves alertness and the information processing speed within the central nervous system, in healthy volunteers.

show abstract

Section: Discussionmentioning

confidence: 54%

Section: Methodsmentioning

confidence: 99%

Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers

Schück

Bentué-Ferrer

Kleinermans

et al. 2002

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Up to 6 hours after a single dose administration lorazepam (1 mg) significantly impaired performance on a tapping test, a continuous performance test, a simple reaction time test, body sway, Sternberg memory scanning test, and on immediate and delayed recall [73].…”

Section: Lorazepammentioning

confidence: 99%

Effects of Sleep Medications on Cognition, Psychomotor Skills, Memory and Driving Performance in the Elderly

Verster¹,

Volkerts²,

Spence

et al. 2007

CPSR

View full text Add to dashboard Cite

Sleep disturbances occur more often in the elderly than in patients in any other age category. Traditional treatment regimens for insomnia in older patients have emphasized benzodiazepines. The useful anxiolytic and hypnotic properties of these agents have made them the most widely prescribed class of drugs in the world. Concern has been expressed however about the significant side effect profile associated with these agents. There is now considerable evidence that all benzodiazepines show significant dose-dependent impaired daytime performance on a variety of memory, cognitive and psychomotor tests. In addition, the risk of falls, hip fractures, and traffic accidents is significantly increased in patients who are treated with benzodiazepines. There is little evidence that benzodiazepine hypnotics are still effective after chronic use. On the other hand, several impairments persist when using these hypnotics over long time. Recently, the nonbenzodiazepine drugs zolpidem and zaleplon have been introduced and are claimed to be relatively safe (i.e. less daytime sedation) when compared to benzodiazepines. Zopiclone, a non-benzodiazepine hypnotic, shows no advantages over benzodiazepines with respect to daytime performance.Several factors may interact with the effects of hypnotics on daytime functioning, including normal cognitive decline during aging, the effects of insomnia itself on daytime functioning, the presence or absence of co-morbid disorders, and pharmacokinetic changes accompanying aging. The impact of hypnotics on daytime performance further depends on various drug-related factors including the administered dose, half-life, time between intake and performance, duration of treatment, gender, and individual differences.In contrast, zolpidem and zaleplon do not significantly impair daytime performance when administered at bedtime at the recommended dose. Although further studies of drug effects in elderly insomniacs are necessary, the available evidence suggests that these short acting and relatively safer non-benzodiazepine hypnotics are a preferred alternative therapy for treating insomnia in the elderly.

show abstract

“…These two studies will support all the preceeding comments and in any case constitute a forceful argument in favour of early studies performed in laboratory conditions. TIATEM [54] was a Phase I clinical study aimed at establishing the cognitive mapping of a substituted benzamide, tiapride, a selective antagonist of the D 2 and D 3 dopaminergic receptors. This study was performed in 12 elderly healthy subjects (average age 69 ± 3 years) following a randomized, crossover, double-blind design comparing one dose of 100 mg tiapride to placebo and to a reference compound, lorazepam at 1 mg.…”

Section: An Example Of This Approach: Tiapridementioning

confidence: 99%

Comparative effects of pharmacotherapy on the maintenance of cognitive function

et al. 2001

View full text Add to dashboard Cite

The quality of human cognitive performance appears today as one of the main components of quality of life, whatever the age. Ageing by itself and most of the diseases affecting the central nervous system alter higher brain functions such as memory, vigilance and attention. Dementia is the most acute example, with a cascade of behavioral and psychological consequences (BPSD), which are the main cause of the caregiver's burden and need specific pharmacotherapy. In this respect, the problem will be the choice of the best drug in situations such as wandering, agitation, violence, and screaming. The psychotropics, however, should not deteriorate the already disturbed cognition of the patients. This is the reason why we propose to establish for each drug, and notably for the antipsychotics, a precise and exact "cognitive mapping"; in other words, to measure the effects of drugs on the different components of cognition. The results of such studies will be predictive of the future phase III clinical trials and therapeutic responses. As an illustration of this approach we shall relate two studies, TIATEM (phase I) and TIAGE (phase III/IV), leading to the determination of a good cognitive safety profile of an atypical neuroleptic drug, tiapride.

show abstract

Effects of tiapride on electroencephalograms and cognitive functions in the elderly

Cited by 11 publications

References 0 publications

Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers

Psychomotor and cognitive effects of piribedil, a dopamine agonist, in young healthy volunteers

Effects of Sleep Medications on Cognition, Psychomotor Skills, Memory and Driving Performance in the Elderly

Comparative effects of pharmacotherapy on the maintenance of cognitive function

Contact Info

Product

Resources

About